Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial

Li Xi; Zhang Li; Jiang Da; Wang Yan; Zang Aimin; Ding Cuimin; Zhao Min; Su Wuyun; Zhang Yan; Zhong Diansheng; Wu Jin; Zhang Cuiying; An Guangyu; Hu Xingsheng; Cheng Gang; Wang Huaqing; Li Yongqun; He Xiaohui; Liu Junli; Liang Li; Ding Lieming; Mao Li; Zhang Shucai

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial

【24h】

Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial

机译：晚期非小细胞肺癌患者患有EGFR外显子21-L858R突变的常规和高剂量icotinib：随机，II期，增加试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Our primary purpose is to explore safety and efficacy of high-dose icotinib in comparison with routine-dose icotinib in patients with non-small cell lung cancer (NSCLC) harboring 21-L858R mutation.

机译：目的：我们的主要目的是探讨高剂量icotinib的安全性和有效性与患有21-L858R突变的非小细胞肺癌（NSCLC）的常规剂icotinib相比。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2020年第13期|共10页
作者
Li Xi; Zhang Li; Jiang Da; Wang Yan; Zang Aimin; Ding Cuimin; Zhao Min; Su Wuyun; Zhang Yan; Zhong Diansheng; Wu Jin; Zhang Cuiying; An Guangyu; Hu Xingsheng; Cheng Gang; Wang Huaqing; Li Yongqun; He Xiaohui; Liu Junli; Liang Li; Ding Lieming; Mao Li; Zhang Shucai;
展开▼
作者单位

Capital Med Univ Beijing TB &

Thorac Tumor Res Inst Beijing Chest Hosp Dept Med Oncol Beijing;

Chinese Acad Med Sci Resp Med Beijing Peoples R China;

Hebei Med Univ Tumor Hosp Hebei Prov Hosp 4 Dept Med Oncol Shijiazhuang Hebei Peoples R China;

Chinese Acad Med Sci &

Peking Union Med Coll State Key Lab Mol Oncol Dept Med Oncol Natl Canc;

Hebei Univ Dept Med Oncol Hebei Key Lab Canc Radiotherapy &

Chemotherapy Baoding Peoples R China;

Hebei Med Univ Hosp 4 Dept Resp Med Shijiazhuang Hebei Peoples R China;

Hebei Chest Hosp Dept Oncol Shijiazhuang Hebei Peoples R China;

Inner Mongolia Med Univ Affiliated Hosp Dept Med Oncol Hohhot Peoples R China;

Hebei Med Univ Affiliated Peoples Hosp Dept Oncol Shijiazhuang Hebei Peoples R China;

Tianjin Med Univ Gen Hosp Dept Oncol Tianjin Peoples R China;

Harbin Med Univ Canc Hosp Dept Head &

Neck &

Genitourinary Oncol Harbin Peoples R China;

Peoples Hosp Inner Mongolia Autonomous Reg Dept Med Oncol Hohhot Peoples R China;

Capital Med Univ Beijing Chao Yang Hosp Dept Med Oncol Beijing Peoples R China;

Chinese Acad Med Sci &

Peking Union Med Coll State Key Lab Mol Oncol Dept Med Oncol Natl Canc;

Beijing Hosp Natl Ctr Gerontol Dept Oncol Beijing Peoples R China;

Tianjin Peoples Hosp Dept Resp Med Tianjin Peoples R China;

Peoples Liberat Army Gen Hosp Med Ctr 6 Resp Dept Beijing Peoples R China;

Chinese Acad Med Sci &

Peking Union Med Coll State Key Lab Mol Oncol Dept Med Oncol Natl Canc;

Hebei Med Univ Xingtai Peoples Hosp Dept Med Oncol Xingtai Peoples R China;

Peking Univ First Hosp Dept Oncol Beijing Peoples R China;

Betta Pharmaceut Co Ltd Hangzhou Peoples R China;

Betta Pharmaceut Co Ltd Hangzhou Peoples R China;

Capital Med Univ Beijing TB &

Thorac Tumor Res Inst Beijing Chest Hosp Dept Med Oncol Beijing;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial [J] . Li Xi, Zhang Li, Jiang Da, Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第13期

机译：晚期非小细胞肺癌患者患有EGFR外显子21-L858R突变的常规和高剂量icotinib：随机，II期，增加试验
2. P2.13-30 High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer with EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study [J] . X. Li, L. Zhang, J. Da, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：P2.13-30高剂量icotinib在先进的非小细胞肺癌中，具有EGFR 21 L858R突变：随机，开放标签增加研究
3. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test [J] . Choi Moon Ki, Hong Jung Yong, Chang Won Jin, Cancer chemotherapy and pharmacology. . 2015,第6期

机译：吉非替尼单药II期治疗未治疗EGFR突变的晚期非小细胞肺癌预治疗患者的II期试验：敏感的EGFR突变试验的意义
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Design, Construction, and Verification of a LATE-PCR and Lights-On/Lights-Off Probe Assay for Mutation Detection in Exons 18-21 of the EGFR Gene: Implications for Molecular Diagnosis of Non-Small Cell Lung Carcinoma [D] . Tetrault, Shana Augustin 2012

机译：用于EGFR基因外显子18-21突变检测的LATE-PCR和开/关灯探针检测的设计，构建和验证：对非小细胞肺癌的分子诊断意义
6. Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials [O] . Antonio Passaro, Bruno Gori, Filippo de Marinis 2013

机译：阿法替尼作为具有EGFR突变的晚期非小细胞肺癌患者的一线治疗：关注LUX-Lung 3和LUX-Lung 6的III期临床试验
7. Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial [O] . Xi Li, Li Zhang, Da Jiang, 2020

机译：晚期非小细胞肺癌患者患有EGFR外显子21-L858R突变的常规和高剂量icotinib：随机，II期，增加试验

Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial

摘要

著录项

相似文献

相关主题

期刊订阅